Ben Leach

At the 11th International Congress on Targeted Therapies in Cancer, The International Journal of Targeted Therapies in Cancer spoke with Dr. Sosman about his conference presentation on advances in immunotherapy in melanoma.

A subgroup analysis showed that certain patients with breast cancer may benefit more from eribulin, and quality of life (QoL) data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

Amid a flurry of new drug approvals in recent years, the American Urological Association (AUA) has issued its first set of guidelines for the management of patients with metastatic castration-resistant prostate cancer (mCRPC).

High doses of interleukin-2 (IL-2) could be used to treat patients with melanoma whose disease has metastasized to the brain, potentially expanding options in a population facing a grim prognosis, according to researchers from Saint Louis University in Missouri.

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence.

A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.

Ado-trastuzumab emtansine received FDA approval in February, and a number of ongoing trials now seek to determine whether the antibody-drug conjugate can be combined with other agents.

Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.

Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.

Researchers have identified a potential predictive marker for survival in cases of mCRC treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug.

Nearly three-fourths of patients with previously untreated advanced NSCLC with specific mutations of EGFR experienced one full year of PFS when given the investigational therapeutic agent dacomitinib.